CN105687192A - Medicine composition for treating dizziness and preparing technology of medicine composition - Google Patents
Medicine composition for treating dizziness and preparing technology of medicine composition Download PDFInfo
- Publication number
- CN105687192A CN105687192A CN201610146932.6A CN201610146932A CN105687192A CN 105687192 A CN105687192 A CN 105687192A CN 201610146932 A CN201610146932 A CN 201610146932A CN 105687192 A CN105687192 A CN 105687192A
- Authority
- CN
- China
- Prior art keywords
- parts
- semen
- radix
- dizziness
- active ingredient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/286—Carthamus (distaff thistle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/288—Taraxacum (dandelion)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/32—Burseraceae (Frankincense family)
- A61K36/328—Commiphora, e.g. mecca myrrh or balm of Gilead
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/39—Convolvulaceae (Morning-glory family), e.g. bindweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/482—Cassia, e.g. golden shower tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/488—Pueraria (kudzu)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/535—Perilla (beefsteak plant)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
- A61K36/638—Ligustrum, e.g. Chinese privet
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/704—Polygonum, e.g. knotweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
- A61K36/714—Aconitum (monkshood)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
- A61K36/746—Morinda
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8964—Anemarrhena
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
- A61K36/8994—Coix (Job's tears)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a medicine composition for treating dizziness. The medicine composition is prepared from 10 kg of difenidol hydrochloride, 30 kg of active ingredients of Chinese medicine, 22.5 kg of dextrin, 22.5 kg of saccharose, 36 kg of starch, 6 kg of carboxymethyl starch sodium, 17.05 kg of 95% ethyl alcohol and 9.95 kg of purified water, all the raw materials are taken and granulated with a conventional method, and 1.50 million tablets are prepared. The difenidol hydrochloride tablets prepared through the method have a remarkable effect on dizziness, are free of toxicity or harm to the human body, free of side effects, low in price, and easy and convenient to prepare, and have wide application prospects.
Description
Technical field
The invention belongs to pharmaceutical technology field, specifically relate to a kind of pharmaceutical composition treating dizziness and preparation technology thereof。
Background technology
Dizziness, is generally also named head rotation dim eyesight, is a kind of common symptom clinically。The lighter is as sat journey, and the time of outbreak is of short duration, and namely the flat sleeping order that closes pacifies a moment;Namely severe one feels very dizzy, it is impossible to stand, and the symptom such as companion sees nausea and vomiting, is in a cold sweat, hand shaking, especially easy generation is with fat, the poor person of body and old people。The feature of its characteristic irregularly shown effect and rear easily recurrence, is called difficult miscellaneous diseases by medical circle。Drug intoxication, motion sickness, arteriosclerosis, hypertension, hypotension, arrhythmia etc., all can cause dizziness。The mistake that spatial orientation sensation subjectivity is known from experience by patient, patient feels surrounding objects or from rotation, or for oscilaltion, the sensation that rolls。It is one of modal main suit in outpatient。Data shows: in crowd, the prevalence of dizziness is 5 ‰, and in general medicine out-patient, about 5% has dizziness, and in department of otorhinolaryngology patient about 7%~15%, Neurology Clinic has 5%~15%, and inpatient has 6%~8% to have vertigo symptoms;In over-65s out-patient, 30% has dizziness, more than 80 years old about 40%;What cause because of dizziness falls in a swoon and accounts for the 6th in the cause of the death of gerontal patient。
Dizziness is the 3rd of outpatient service common sympton, and vast majority of people all experiences this disease in life。The patient suffering from vertigo generally has following symptom: blood pressure, perspires, pale complexion, diarrhoea;Deafness, tinnitus, ear is vexed;Dark and dim eyesight, diplopia, blurred vision;Neck portion or shoulder arm pain, upper limb numbness, limitation of activity;Headache, disturbance of consciousness, sensorimotor obstacle, language or dysarthria etc., in the medicine preventing and treating dizziness, domestic at present primarily focus on antiallergic and relaxing smooth muscle medicine, example hydrochloric acid diphenidol, but great majority have the side effect such as drowsiness, xerostomia, are abroad normally applied revitalizer, such as amfetamine or methylphenidate coupling east henbane alkali or dimenhydrinate, but also there is more side effect。
Motherland's medical science has complete theory and therapy system in treatment vertigo, and has original curative effect。Dizziness disease, successive dynasties doctor's nationality is recorded a lot of, as: " Plain Questions the most pure virginity to be discussed greatly " is thought: " all wind trembling and dizziness, come under liver ";" the big puzzled opinion of bier " is pointed out: " in item in old pathogen, because meeting the void of its body ... enter brain then vertigo, it is anxious that vertigo then draws order system, and order system is anxious then dizzy to turn; " pathogenic factor long term in cervical vertebra, general debility with deficiency of QI in addition, skeleton regression, causing neck blood stasis, passages through which vital energy circulates loses supports, and causes dizzy
All diseases such as dizzy, stiffness of the nape occur;" Ling Shu Miraculous Pivot or Divine Axis defends gas " is thought: " deficiency of the upper causing dizziness ", also has " QI of the upper portion of the body being insufficient " in Miraculous Pivot, and " deficiency of marrow-reservoir " etc. causes dizzy because of void。Han dynasty Zhang Zhongjing thinks that phlegm retention is one of reason of dizziness morbidity, has again six climate exopathogens, damaged by excess of seven emotions to cause later dizzy, and dificiency in lower-JIAO causes dizzy etc.。According to clinical practice, dizziness is in close relations with the liver of theory of Chinese medical science。Excessive rising of liver-YANG can directly send out dizziness, or because of melancholy angry for a long time, stagnated QI transforming into fire, make liver-yin secretly consume, wind sun rises dynamic, pathogen upward attacking orifices in head, and sending out is dizziness, or chronic deficiency of kidney-YIN, the liver failing to be nourished, so that deficiecny of liver-YIN, excessive rising of liver-YANG, sends out as dizziness。
Western medicine is theoretical: dizziness needs, from improving cerebral cortex regulatory function, regulate and control autonomic excitement and suppress function, promotes that neural relative equilibrium reaches to control the treatment of dizziness angle;From tcm theory: mainly entering Liver Channel, fire, suppressing the hyperactive liver to relieve the wind syndrome are let out in liver heat removing。Therefore seek a kind of high-efficiency low-toxicity, the Chinese medicine and western medicine compound drug for the treatment of both the principal and secondary aspects of a disease is a pendulum technical problem in face of medical circle。
Summary of the invention
It is an object of the invention to provide that a kind for the treatment of both the principal and secondary aspects of a disease, side effect be little, safe ready, cheap pharmaceutical composition and preparation technology thereof for treating dizziness。Its purpose is to solve treatment vertigo, overcome Western medicine difenidol hydrochloride effect not notable, and easily repeatedly, the problem that toxic and side effects is big, reach the purpose for the treatment of both the principal and secondary aspects of a disease。
The present invention is with reference to invaluable experience to the pathogenetic understanding of vertigo and treatment of motherland medical science, consult existing reasonable formula, determination for the treatment of based on pathogenesis obtained through differentiation of symptoms and signs, according to Chinese Pharmacopoeia and pharmacology compatibility, pushing away Chen Zhixin gain to some extent, determination for the treatment of based on pathogenesis obtained through differentiation of symptoms and signs is always up the core theory of Chinese medicine disease, how to take into account secondary pathogenesis for main pathogenesis medication simultaneously, taking into account the treatment of general character and individual character, thus at utmost embodying intension and the extension of Chinese traditional treatment disease, being a realistic problem of Chinese patent medicine compatibility。Inventor, for the main pathogenesis characteristics of dizziness, puts into practice according to doctor's row for many years in conjunction with a large amount of formula, by the research to Chinese medicine, and in conjunction with dialectical demonstration, in many ways collect the length of many families, seek therapeutic regimen, obtaining technical solution of the present invention, its all medicine share, and brings out the best in each other。
For realizing the object of the invention, the technical solution used in the present invention is as follows:
A kind of pharmaceutical composition for treating dizziness, it is prepared by following raw material and obtains:
Difenidol hydrochloride 37.5kg, dextrin 22.5kg, sucrose 22.5kg, starch 36kg, carboxymethyl starch sodium 6kg, 95% ethanol 17.05kg, purified water 9.95kg。
Take above-mentioned raw materials, conventionally pelletize, prepare 1,500,000, tablet。
Preferably, the pharmaceutical composition of the present invention, it is prepared by following raw material and obtains:
Difenidol hydrochloride 10kg, active ingredient of Chinese herbs 30kg, dextrin 22.5kg, sucrose 22.5kg, starch 36kg, carboxymethyl starch sodium 6kg, 95% ethanol 17.05kg, purified water 9.95kg。
Take above-mentioned raw materials, conventionally pelletize, prepare 1,500,000, tablet。
Described active ingredient of Chinese herbs, it is prepared by the raw material of following weight and obtains:
Radix Salviae Miltiorrhizae 35 parts, 35 parts of Flos Carthami, Ramulus Uncariae Cum Uncis 35 parts, Herba Taraxaci 35 parts, Rhizoma Imperatae 30 parts,
Poria cum Radix Pini 30 parts, Caulis Polygoni Multiflori 30 parts, Fructus Ligustri Lucidi 30 parts, Radix Puerariae 28 parts, Semen Cassiae 28 parts,
Radix Polygoni Multiflori 25 parts, Cortex Moutan 25 parts, the Rhizoma Anemarrhenae 25 parts, Semen Cuscutae 25 parts, Myrrha 20 parts,
Radix Paeoniae Rubra 20 parts, Semen oryzae sativae 20 parts, Semen Coicis 20 parts, Semen Citri Reticulatae 20 parts, Cortex Cinnamomi 20 parts,
Radix Aconiti Lateralis Preparata 18 parts, Folium Perillae 15 parts, Radix Morindae Officinalis 15 parts。
The preparation method of described active ingredient of Chinese herbs is:
(1) above-mentioned raw materials is weighed standby;
(2) Flos Carthami, Herba Taraxaci, Rhizoma Imperatae, Poria cum Radix Pini, Semen Cassiae, Cortex Moutan, Myrrha, Semen oryzae sativae, Semen Coicis, Semen Citri Reticulatae, Cortex Cinnamomi, Folium Perillae boiling are taken, first time adds 4 times of weight water, decoct 1 hour, obtain filtrate and medicinal residues after filtration, medicinal residues are added 3 times of weight water and decocts 1 hour, after filtration, obtain filtrate, merge twice filtrate, filtrate after merging is condensed into the extractum that density is 1.2g/ml, and 60 DEG C dried, pulverizes and obtains composite I;
(3) take surplus stock and add 2 times of weight 75%(volume ratios) ethanol, reflux, extract, 2 times, each 1 hour, extracting solution merged, and is concentrated into the extractum that density is 1.2g/ml, and 60 DEG C are dried, pulverizes and obtains Complex II;
(4) namely Homogeneous phase mixing composite I, II obtain active ingredient of Chinese herbs。
The medicine of the present invention can adopt the conventional method in existing pharmaceutical field to produce, it is necessary to time can add various pharmaceutically acceptable carrier。Described carrier includes the conventional excipient of pharmaceutical field, filler, binding agent, wetting agent, disintegrating agent, absorption enhancer, surfactant, absorption carrier, lubricant etc.。
Usage and dosage, one time 1,3 times on the one。
Technical solutions according to the invention are on the clinical experience basis of Chinese traditional treatment dizziness, in conjunction with modern pharmacy achievement develop with the compound preparation of Integrated TCM。Chinese medicine and Western medicine are effectively combined, there is dispelling wind and removing obstruction in the collateral very strongly, flat dizzy dizzy effect of dispelling, symptom can be improved rapidly, stop disease, dizziness is had effect of healing, overcomes prior art Chinese medicine onset slow and the shortcoming such as toxicity is big, reach the purpose for the treatment of both the principal and secondary aspects of a disease。
The component of medicine of the present invention all adopts natural raw material of Chinese medicine, and it prepares simplicity, and medicine source is extensive, with low cost, it adopts different extracting method to obtain its effective ingredient to greatest extent, it then follows the prescriptions principle of the traditional Chinese medical science, all medicines share, and bring out the best in each other, and invention formulation dose is little, effective ingredient is prone to release, absorbs fast, and bioavailability is high, enabling drug effect to give full play to, verify by clinic application, it is evident in efficacy reliably, mild in medicine property and, toxic and side effects does not occur, has a extensive future。
Detailed description of the invention
Embodiment 1
A kind of pharmaceutical composition for treating dizziness and preparation technology thereof, it is prepared by following raw material and obtains:
Difenidol hydrochloride 37.5kg, dextrin 22.5kg, sucrose 22.5kg, starch 36kg, carboxymethyl starch sodium 6kg, 95% ethanol 17.05kg, purified water 9.95kg。
Take above-mentioned raw materials, conventionally pelletize, prepare 1,500,000, tablet。
Usage and dosage, one time 1,3 times on the one, 7 days be a course for the treatment of。
Embodiment 2
A kind of pharmaceutical composition for treating dizziness and preparation technology thereof, it is prepared by following raw material and obtains:
Difenidol hydrochloride 10kg, active ingredient of Chinese herbs 30kg, dextrin 22.5kg, sucrose 22.5kg, starch 36kg, carboxymethyl starch sodium 6kg, 95% ethanol 17.05kg, purified water 9.95kg。
Take above-mentioned raw materials, conventionally pelletize, prepare 1,500,000, tablet。
Described active ingredient of Chinese herbs, it is prepared by the raw material of following weight and obtains:
Radix Salviae Miltiorrhizae 35 parts, 35 parts of Flos Carthami, Ramulus Uncariae Cum Uncis 35 parts, Herba Taraxaci 35 parts, Rhizoma Imperatae 30 parts,
Poria cum Radix Pini 30 parts, Caulis Polygoni Multiflori 30 parts, Fructus Ligustri Lucidi 30 parts, Radix Puerariae 28 parts, Semen Cassiae 28 parts,
Radix Polygoni Multiflori 25 parts, Cortex Moutan 25 parts, the Rhizoma Anemarrhenae 25 parts, Semen Cuscutae 25 parts, Myrrha 20 parts,
Radix Paeoniae Rubra 20 parts, Semen oryzae sativae 20 parts, Semen Coicis 20 parts, Semen Citri Reticulatae 20 parts, Cortex Cinnamomi 20 parts,
Radix Aconiti Lateralis Preparata 18 parts, Folium Perillae 15 parts, Radix Morindae Officinalis 15 parts。
The preparation method of described active ingredient of Chinese herbs is:
(1) above-mentioned raw materials is weighed standby;
(2) Flos Carthami, Herba Taraxaci, Rhizoma Imperatae, Poria cum Radix Pini, Semen Cassiae, Cortex Moutan, Myrrha, Semen oryzae sativae, Semen Coicis, Semen Citri Reticulatae, Cortex Cinnamomi, Folium Perillae boiling are taken, first time adds 4 times of weight water, decoct 1 hour, obtain filtrate and medicinal residues after filtration, medicinal residues are added 3 times of weight water and decocts 1 hour, after filtration, obtain filtrate, merge twice filtrate, filtrate after merging is condensed into the extractum that density is 1.2g/ml, and 60 DEG C dried, pulverizes and obtains composite I;
(3) take surplus stock and add 2 times of weight 75%(volume ratios) ethanol, reflux, extract, 2 times, each 1 hour, extracting solution merged, and is concentrated into the extractum that density is 1.2g/ml, and 60 DEG C are dried, pulverizes and obtains Complex II;
(4) namely Homogeneous phase mixing composite I, II obtain active ingredient of Chinese herbs。
Embodiment 3
One, toxicity test
This experiment adopts healthy SD rat 40, it is divided into two groups, often group 20, the medicine of oral administration embodiment 1, embodiment 2 preparation respectively, successive administration 30 days, during it be observed that rat administration and after drug withdrawal, within 1 week, growth of animal state, movable diet, hematology, blood biochemical analysis, organs and tissues structure and routine urinalysis etc. all have no significant effect, it was shown that clinical drug safety is reliable。
Two, after rat is rotated by the preparation of embodiment 2 preparation, property nystagmus has obvious inhibitory action, the tolerance time of vestibule irriate can be extended, alleviate vestibule autonomic nervous dysfunction, expansion blood vessel can be played, improve microcirculation, increase blood flow, alleviate dizziness and tinnitus, deaf effect;
Embodiment 4
Clinical data
1. choose outpatient's totally 90 example with complete case。Being randomly divided into two groups, 1 group of 45 example of embodiment, 2 group of 45 example of embodiment, between above each group。No significant difference (P > 0.05), has comparability。
2. diagnostic criteria adopts Cervical Spondylosis diagnostic criteria and the typing standard of State Administration of Traditional Chinese Medicine's nineteen ninety-five promulgation, with reference to " new Chinese medicine guideline of clinical investigations " (trying): (1) cervical vertigo, history of can dampinging off;(2) rotation neck levies the positive;(3) X-ray film has abnormal finding;(4) accompany sympathetic symptoms more。
Exclusion standard (1) eye source property, aural vertigo;(2) basilar artery insufficiency and neurosis and intracranial tumor etc. caused by vertebral artery I section and III section of pressurized of vertebral artery。
3. Therapeutic Method:
Embodiment 1 group, give embodiment 1 preparation tablet, one time 1,3 times on the one, 7 days be a course for the treatment of。
Embodiment 2 groups, give embodiment 2 preparation tablet, one time 1,3 times on the one, 7 days be a course for the treatment of。
4. criterion of therapeutical effect is with reference to " new Chinese medicine guideline of clinical investigations " (trying)。
Curing: clinical symptoms, sign disappear or substantially disappear, syndrome integral reduces >=95%;Effective: clinical symptoms, sign change
Kind obvious, syndrome integral reduces >=70%;Effective: clinical symptoms, sign all take a favorable turn, syndrome integral reduces >=30%;Invalid: clinical symptoms, sign are not improved, even increase the weight of, syndrome integral is less than 30%。
Criterion of therapeutical effect with reference to State Administration of Traditional Chinese Medicine's nineteen ninety-five is quantified, observe two groups of comparisons to main symptom and time card improvement degree, represent with integration method, complying with weight degree in gently different: primary symptom is dizzy, dizzy remembers 2 points, 4 points, 6 points respectively, secondary disease is had a headache, item is tight, shoulder back of the body distending pain etc. remembers 1 point, 2 points, 3 points respectively。
Statistical method measurement data represents with mean ± standard deviation, compares and use paired t-test in group。All data use SPSS10.0 software to carry out statistical analysis, if P < 0.05 is that difference is statistically significant。Two groups of clinical efficacies are in Table 1:
Table 1: efficacy result
Group | Example time | Cure | Effective | Effectively | Invalid | Total effective rate |
Embodiment 2 groups | 45 | 19 | 13 | 12 | 1 | 97.8% |
Embodiment 1 group | 45 | 15 | 9 | 7 | 14 | 68.9% |
Above-mentioned each Chinese medicine and western medicine that the present invention adopts makes compatibility mutually, its collaborative effect of curing the disease can be played, there is between each composition of raw material of Chinese medicine used drug effect be interweaved and mutually promote and coordinate usefulness, according to clinical verification, dizziness is had good adjuvant treatment effect, in the applicant's medical practice for many years, the case Numerous cured, all obtain good effect, and with low cost, alleviate the burden of patient。
Claims (4)
1., for treating a pharmaceutical composition for dizziness, it obtains according to the preparation of following technique:
Take difenidol hydrochloride 37.5kg, dextrin 22.5kg, sucrose 22.5kg, starch 36kg, carboxymethyl starch sodium 6kg, 95% ethanol 17.05kg, purified water 9.95kg, conventionally pelletize, prepare 1,500,000, tablet。
2., for treating a pharmaceutical composition for dizziness, it obtains according to the preparation of following technique:
Take difenidol hydrochloride 10kg, active ingredient of Chinese herbs 30kg, dextrin 22.5kg, sucrose 22.5kg, starch 36kg, carboxymethyl starch sodium 6kg, 95% ethanol 17.05kg, purified water 9.95kg, conventionally pelletize, prepare 1,500,000, tablet。
3. the pharmaceutical composition described in claim 1-2, it is characterised in that described active ingredient of Chinese herbs is prepared by the raw material of following weight parts and obtained:
Radix Salviae Miltiorrhizae 35 parts, 35 parts of Flos Carthami, Ramulus Uncariae Cum Uncis 35 parts, Herba Taraxaci 35 parts, Rhizoma Imperatae 30 parts,
Poria cum Radix Pini 30 parts, Caulis Polygoni Multiflori 30 parts, Fructus Ligustri Lucidi 30 parts, Radix Puerariae 28 parts, Semen Cassiae 28 parts,
Radix Polygoni Multiflori 25 parts, Cortex Moutan 25 parts, the Rhizoma Anemarrhenae 25 parts, Semen Cuscutae 25 parts, Myrrha 20 parts,
Radix Paeoniae Rubra 20 parts, Semen oryzae sativae 20 parts, Semen Coicis 20 parts, Semen Citri Reticulatae 20 parts, Cortex Cinnamomi 20 parts,
Radix Aconiti Lateralis Preparata 18 parts, Folium Perillae 15 parts, Radix Morindae Officinalis 15 parts。
4. the pharmaceutical composition described in claim 1-3, it is characterised in that the preparation method of described active ingredient of Chinese herbs is:
(1) above-mentioned raw materials is weighed standby;
(2) Flos Carthami, Herba Taraxaci, Rhizoma Imperatae, Poria cum Radix Pini, Semen Cassiae, Cortex Moutan, Myrrha, Semen oryzae sativae, Semen Coicis, Semen Citri Reticulatae, Cortex Cinnamomi, Folium Perillae are taken, mixing, boiling, first time adds 4 times of weight water, decoct 1 hour, obtain filtrate and medicinal residues after filtration, medicinal residues are added 3 times of weight water and decocts 1 hour, after filtration, obtain filtrate, merge twice filtrate, filtrate after merging is condensed into the extractum that density is 1.2g/ml, and 60 DEG C dried, pulverizes and obtains composite I;
(3) take surplus stock mixing, add 2 times of weight 75%(volume ratios) ethanol, reflux, extract, 2 times, each 1 hour, extracting solution merged, and is concentrated into the extractum that density is 1.2g/ml, and 60 DEG C are dried, pulverized acquisition Complex II;
(4) namely Homogeneous phase mixing composite I, II obtain active ingredient of Chinese herbs。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610146932.6A CN105687192A (en) | 2016-03-15 | 2016-03-15 | Medicine composition for treating dizziness and preparing technology of medicine composition |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610146932.6A CN105687192A (en) | 2016-03-15 | 2016-03-15 | Medicine composition for treating dizziness and preparing technology of medicine composition |
Publications (1)
Publication Number | Publication Date |
---|---|
CN105687192A true CN105687192A (en) | 2016-06-22 |
Family
ID=56220554
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610146932.6A Pending CN105687192A (en) | 2016-03-15 | 2016-03-15 | Medicine composition for treating dizziness and preparing technology of medicine composition |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105687192A (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110638775A (en) * | 2019-10-25 | 2020-01-03 | 仁和堂药业有限公司 | Difenidol hydrochloride tablet and application thereof |
CN110638776A (en) * | 2019-10-25 | 2020-01-03 | 仁和堂药业有限公司 | Preparation process of difenidol hydrochloride tablets |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103961609A (en) * | 2014-05-24 | 2014-08-06 | 山东仁和堂药业有限公司 | Difenidol hydrochloride and preparation method thereof |
CN105326803A (en) * | 2015-12-05 | 2016-02-17 | 翔宇药业股份有限公司 | Difenidol hydrochloride tablets for treating motion sickness and preparation method thereof |
-
2016
- 2016-03-15 CN CN201610146932.6A patent/CN105687192A/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103961609A (en) * | 2014-05-24 | 2014-08-06 | 山东仁和堂药业有限公司 | Difenidol hydrochloride and preparation method thereof |
CN105326803A (en) * | 2015-12-05 | 2016-02-17 | 翔宇药业股份有限公司 | Difenidol hydrochloride tablets for treating motion sickness and preparation method thereof |
Non-Patent Citations (2)
Title |
---|
彭逢春等: "中药复方治疗眩晕的用药频数分析", 《世界中西医结合杂志》 * |
王立忠: "眩晕病的辨证思路与方法", 《河南中医》 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110638775A (en) * | 2019-10-25 | 2020-01-03 | 仁和堂药业有限公司 | Difenidol hydrochloride tablet and application thereof |
CN110638776A (en) * | 2019-10-25 | 2020-01-03 | 仁和堂药业有限公司 | Preparation process of difenidol hydrochloride tablets |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105326803A (en) | Difenidol hydrochloride tablets for treating motion sickness and preparation method thereof | |
CN102631579B (en) | Oral Chinese herbal preparation for treating post-traumatic brain syndrome | |
CN105770591A (en) | Pharmaceutical preparation for treating dizziness and preparation method thereof | |
CN106362104A (en) | Pharmaceutical composition for treating polycystic ovary syndrome in adolescence | |
CN101700336B (en) | Chinese herba preparation for curing craniocerebra trauma residual headache and preparation method | |
CN105687192A (en) | Medicine composition for treating dizziness and preparing technology of medicine composition | |
CN103006953A (en) | Medicament for treating insomnia and preparation method thereof | |
CN104043045A (en) | Pharmaceutical composition for treating optic atrophy | |
CN100475249C (en) | Chinese medicinal composition for curing migraine | |
CN104667199A (en) | Pharmaceutical preparation for treating mental anxiety and application of pharmaceutical preparation | |
CN103961609A (en) | Difenidol hydrochloride and preparation method thereof | |
CN106237268A (en) | One treats schizoid pharmaceutical composition and application thereof | |
CN102716260B (en) | Medicine for fast improving sperm quality and sexual function | |
CN105833043A (en) | Application of traditional Chinese medicine composition in preparation of medicine for treating primary hypertension | |
CN101342208B (en) | Chinese medicinal composition for treating coronary disease, stenocardia, arrhythmia and preparation method thereof | |
CN104491483A (en) | Traditional Chinese medicine composition for improving allergic diseases, preparation method and application thereof | |
CN104689230A (en) | Method for preparing traditional Chinese medicine preparation for treatment of vertigo | |
CN104225468A (en) | Preparation for preventing dizziness during power overhead work | |
CN104587396A (en) | Preparation for preventing dizziness caused by power overhead operation | |
CN102949513A (en) | Traditional Chinese medical health protection product for alleviating anxiety neurosis and preparation method thereof | |
CN115737778B (en) | Traditional Chinese medicine preparation with pressure regulating effect | |
CN101683458B (en) | Application of a traditional Chinese medicine composition in preparation of medicament for treating vertigo | |
CN101947263A (en) | Medicament for treating neurasthenia and insomnia | |
CN108653526B (en) | Traditional Chinese medicine formula for treating myasthenia gravis | |
CN106344818A (en) | Method for preparing traditional Chinese medicine composition for treating migraine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160622 |
|
RJ01 | Rejection of invention patent application after publication |